SAN DIEGO, April 12 /PRNewswire/ -- Medinox, Inc. in Carlsbad, California and Orient Europharma in Taiwan announce today that they have entered into a partnering agreement to develop and market NOX-100, a new anti-hypotensive drug. Under the terms of the agreement, Orient Europharma holds the exclusive distribution rights of NOX-100 in Taiwan, China, Korea, Australia, New Zealand and Southeast Asia. Medinox retains the marketing rights in the United States, Japan and Europe.
Intradialytic hypotension (IH) is a significant complication of routine hemodialysis in end-stage renal disease patients. Complications of IH include headache, muscle cramps, and increase in mortalities. At present, there is no FDA-approved therapy available for treating and/or preventing IH.
About Medinox, Inc.
Medinox is a leader in anti-nitric oxide therapeutics and is developing a broad technology platform to address several unmet medical needs including hemodialysis, cardiopulmonary bypass surgery and septic shock. In addition to its nitric oxide technology, Medinox is also developing new and safer NSAID prodrugs for treating arthritic patients. For information about Medinox and its products, please visit the Company's website at http://www.medinox.com/, or contact Monte Lai, Ph.D., President & CEO of Medinox, Inc., at email@example.com.